Muhlenkamp & CO Inc Macrogenics Inc Transaction History

Muhlenkamp & CO Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 11, 2018	SELL	$18.89 - $32.46 $198,628 - $341,316	-10,515 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$16.19 - $20.3 $36,217 - $45,411	-2,237 Reduced 17.54%	10,515 $200,000
Q3 2017 Nov 13, 2017	SELL	$15.52 - $18.94 $6,440 - $7,860	-415 Reduced 3.15%	12,752 $236,000
Q2 2017 Aug 11, 2017	BUY	N/A	13,167	13,167 $231,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Muhlenkamp & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Muhlenkamp & CO Inc with notifications on news.